Gann Ting, Ph.D.
National Institute of Cancer Research
- Ph.D., Department of Chemistry, University of Tennessee, USA, 1973
- MS., Institute of Atom Science, National Tsing Hua University, Taiwan, 1968
- Visiting Professor, National Institute of Cancer Research, National Health Research Institutes, Taiwan (2004-present)
- Senior Investigator, Institute of Nuclear EnergyResearch, Taiwan(2003)
- Project Manager, Diagnostic Radiopharmaceutical Technology Development Project, Department of Science and Technology, Ministry of Economics Affairs, Taiwan (2000-2003)
- Acting Director, Institute of Nuclear EnergyResearch, Taiwan (2002)
- Deputy Director, Institute of Nuclear EnergyResearch, Taiwan (1993-2002)
- Project Manager, Establishment of INER Compact Cyclotron and Isotope Production Facility, Institute of Nuclear EnergyResearch, Taiwan (1990-1993)
- Senior Researcher and Founding Director, Radioisotope Application Division, Institute of Nuclear Energy Research, Taiwan (1988-1993)
- Senior Researcher and Director, Applied Chemistry Division, Nuclear Chemistry Division and Radioisotope Application Division, Institute of Nuclear Energy Research, Taiwan (1976-1983)
- Adjunct Associate Professor, Department of Chemistry and Department of Chemical Engineering, Chung-Cheng Institute of Technology and National Taiwan University, Taiwan (1973-1984)
- Associate Chemist and PI, Applied Chemistry Division, Institute of Nuclear EnergyResearch, Taiwan (1973-1976)
- Research Scientist, Reactor Chemistry and Chemical Engineering Division, Oak Ridge National Laboratory, USA (1970-1973)
RESEARCH INTERESTSDr. Ting's current major works are research on the design and preparation of nano-targeted combination radiochemotherapeutics, molecular imaging and preclinical animal studies of passive nano-liposome and active nano-immunoliposomes drug delivery. Through the collaborations and partnerships of multi-institutes and multi-disciplines, research on the development of novel multifunctional and multivalent nano-targeted diagnostics and therapeutics will be carrying out from preclinical animal studies to translational research for treatment of tumors and ascites. The research on the integration of nanotechnology, biotechnology and nuclear technology will help and accelerate the success of the new cancer nano-targeted radiopharmaceuticals development and applications from the preclinical to the translational investigations.
RESEARCH ACTIVITIES & ACCOMPLISHMENTSThrough the cancer nano-targeted radiopharmaceuticals research and development project integration and implementation strategies, the alliance partnerships and collaborations of multi-institutes and multi-disciplines networks (NHRI/INER/NYMU/TLC/TVGH) have been established from 2004 to 2007. The major platform technologies comprising nanoliposome drug delivery technologies, molecular biotargeted technologies, radiochemistry technologies, in vivo molecular imaging technologies, will be established. The major research and development achievements for this project include (1) Having completed the research on the preparation and characterization of two passive nano-targeted radiopharmaceuticals and two passive combination bimodality nano-targeted radiochemotherapeuticals; (2) Having completed and proceed preclinical studies of in vitro stability, pharmacokinetics, biodistributions and radiation dosimetry assessments of those four drugs on tumor and ascites animal models; (3) Having applied in vivo nuclear and optical molecular imaging techniques to study tumors and ascites targeting, targeted therapeutic efficacy and therapeutic response. The tumor regression, the therapeutic efficacy of nano-targeted drugs, and the combination or synergistic effect of bimodality nano-targeted drugs have been demonstrated. The research progress goals and milestones of this project have been successfully achieved. Two US and ROC patents were drafted and filed, three SCI journal papers have been published, six poster papers have been presented in the international symposium in 2007.
HONORS & AWARDS
- Outstanding National Honor Scientist Award, Executive Yuan, ROC, 2002.
- Excellent Research Project Manager Award, Ministry of Economic Affairs, ROC, 2001.
- Outstanding National Service Contribution Award, Examination Yuan, ROC, 2000.
- Chou's Memorial Award, Chinese Nuclear Energy Society, ROC, 1997.
- National Service Model Award, Executive Yuan, ROC, 1997.
- Six Times Distinguished Scientific Research Award, Executive Yuan, ROC, 1995-2000.
- Chan's Best Research Paper Award, Chinese Society of Engineering, ROC, 1986
- Eleven Awards and Certifications on Scientific Research Achievements, Ministry of National Defense and Executive Yuan, ROC, 1974-1987
- Chen LC, Chang CH, Yu CY, Chang YJ, Hsu WC, Ho CL, Yeh CH, Luo TY, Lee TW and Ting G*.Biodistribution, Pharmacokinetics and Imaging of 188Re-BMEDA-Labeled Pegylated Liposomes after Intraperitoneal Injection in a C26 Colon Carcinoma Ascites Mouse Model. Nuclear Medicine And Biology, 34; 415-423, 2007. (* = Corresponding Author)
- ChangYJ,Chang CH, ChangTJ, Yu CY, Chen LC, Jan ML, Luo TY, Lee TW and Ting G*. Biodistribution, Pharmacokinetics and MicroSPECT/CT Imaging of 188Re-BMEDA-Liposome in a C26 Murine Colon Carcinoma Solid Tumor Animal Model. Anticancer Research, 27; 2217-2226, 2007. (* = Corresponding Author)
- Chen CC, Hwang JJ, Ting G, Tseng YL, Wang SJ and Whang-Peng J. Monitoring and Quantitative Assessment of Tumor Burden Using In Vivo Bioluminescence. Journal of Nuclear Instruments and Methods in Physics Research Section A, 571:437-441, 2007.
- Lee WC, Chen CC, Chang YF, Wang HE, Tseng YL, Ting G and Hwang JJ. Therapeutic efficacy of 111In-DTPA/VNB-liposome on human colorectal adenocarcinoma HT-29/luc mouse xenografts. Journal of Nuclear Instruments and Methods in Physics Research Section A, 569: 497-504, 2006.
- Yu HM, Lue YC, Heish NN, Hwang JJ, Wang SJ, Ting G and Wang HE. Internal radiotherapy and dosimetric study for 111In/177Lu-pegylated liposomes conjugates in tumor bearing mice. Journal of Nuclear Instruments and Methods in Physics Research Section A, 569:533-537, 2006.
- Weng YH, Yen TC, Ting G, et.al. Sensitivity and spectivity of Tc-99m-TRODAT-1 SPECT imaging in differenting patients with idiopathic Parkinson??s disease from health subjects. J. Nucl. Med. 45:393-401, 2004.
- Ye XX, Hwang JJ, Ting G, et.al. Microautography of I-123ADAM in mice treated with fluoxetine and serotonin reuptake inhibitors. Nuclear Medicine and Biology, 31:557-562, 2004.
- ROC Patent No.248366 "Method for preparation radiolabeled iodine IudR for treatment of liver cancer"; Granted February 1, 2006.
- ROC Patent No.202577 "Method for preparation of high specific activity 188Retherapeutic injections"; Granted May 1, 2003.
- US Patent No.5889146 "Methd for Synthesis of Bifunctional Chelating Agents-Peptides"; Granted March 30, 1999.
- EU Patent No.054623B1 "Method for Synthesis and Tc-99m labelling of ?-aloxyisobutyl isonitrile"; Granted March 1, 1995.
- US Patent No.521070 "Method for Synthesis and Tc-99m labelling of ? aloxyisobutyl isonitrile"; Granted May 11,1993. (INER licensed to US CardinalHealth, 2005)